Tag: VOYAGER PAD

Latest VOYAGER PAD analysis finds no mortality and improved limb outcomes...

Given the absence of a safety signal in data from the VOYAGER PAD trial, a new analysis examined the potential benefit of drug-coated device...

Janssen submits application to US FDA for new indication to expand...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the US Food and...

Endovascular late-breaking trials presented at TCT 2020

Findings from a series of late-breaking trials in the endovascular field were presented recently at TCT Connect (14–18 October, virtual), the 32nd annual scientific...
rivaroxaban

Patients with multiple revascularisations are at higher risk of acute limb...

Symptomatic peripheral arterial disease (PAD) patients undergoing recurrent lower extremity revascularisation have higher rates of ischaemic events, particularly acute limb ischaemia, than those patients...